Extended Data Fig. 2: Co-occurring alterations in patients with RET fusions in the ARROW trial at study entry. | Nature Medicine

Extended Data Fig. 2: Co-occurring alterations in patients with RET fusions in the ARROW trial at study entry.

From: Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Extended Data Fig. 2

a12 patients from the efficacy population did not have any genomics carried out except CRF before the first treatment and were therefore not included. bTwo patients with colorectal cancer and one patient with cholangiocarcinoma were excluded from efficacy analyses due to additional co-occurring driver alterations of PIK3CB E1051G, KRAS Q61H and BRAF V600E, respectively. After enrollment, although the patients were allowed to continue on-study, considering concurrent activating events the sponsor later excluded these patients from the efficacy cohort as the concurrent drivers were adjudicated centrally.

Back to article page